Abdallah Mahamoud
Centre national de la recherche scientifique
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Abdallah Mahamoud.
FEBS Letters | 2011
Jean-Michel Bolla; Sandrine Alibert-Franco; Jadwiga Handzlik; Jacqueline Chevalier; Abdallah Mahamoud; Gérard Boyer; Katarzyna Kieć-Kononowicz; Jean-Marie Pagès
Regarding bacterial susceptibility towards antibacterial agents, membrane permeability is part of the early bacterial defense. The bacterium manages the translocation process, influx and efflux, to control the intracellular concentration of various molecules. Antibiotics and biocides are substrates of these mechanisms and the continuing emergence of multidrug resistant isolates is a growing worldwide health concern. Different strategies could be proposed to bypass the bacterial membrane barrier, comprising influx and efflux mechanisms, in order to restore the activity of antibiotics against resistant bacteria.
Current Drug Targets | 2006
Abdallah Mahamoud; Jacqueline Chevalier; Anne Davin-Regli; Jacques Barbe; Jean-Marie Pagès
Efflux pumps protect the bacterial cell by expelling toxic compounds before they reach intracellular targets. Because this mechanism actively contributes to the resistance of a given bacterium to more than one class of antibiotics, molecules that are able to block the relevant efflux pump are of potential significance to combat drug resistance caused by efflux pumps. Different quinoline derivatives including alkoxy, alkylamino, thioalkoxy and chloroquinolines have been previously reported to make Enterobacter aerogenes resistant isolates that over express the mechanism of efflux, noticeably more susceptible to structurally unrelated antibiotics. In addition, various quinoline derivatives significantly increase the intracellular concentration of chloramphenicol as reported with other inhibitors, thereby suggesting the inhibition of the drug transport by AcrAB-TolC pump, which is fully active in the clinicaly resistant isolates investigated. Here, we discuss the respective properties of this molecular family, taking into account the recent insights into the structural data of AcrB pump.
Antimicrobial Agents and Chemotherapy | 2004
Jacqueline Chevalier; Jérôme Bredin; Abdallah Mahamoud; Monique Malléa; Jacques Barbe; Jean-Marie Pagès
ABSTRACT In Enterobacter aerogenes and Klebsiella pneumoniae, efflux provides efficient extrusion of antibiotics and contributes to the multidrug resistance phenotype. One of the alkoxyquinoline derivatives studied here, 2,8-dimethyl-4-(2′-pyrrolidinoethyl)-oxyquinoline, restores noticeable drug susceptibility to resistant clinical strains. Analyses of energy-dependent chloramphenicol efflux indicate that this compound inhibits the efflux pump mechanism and improves the activity of structurally unrelated antibiotics on multidrug-resistant E. aerogenes and K. pneumoniae isolates.
Journal of Pharmacy and Pharmacology | 2000
Madeleine Castaing; Pierre Brouant; Alain Loiseau; Christiane Santelli-Rouvier; Maurice Santelli; Sandrine Alibert-Franco; Abdallah Mahamoud; Jacques Barbe
This study was designed to test the hypothesis that lipophilic cationic drugs with only roughly similar structures mediate the reversal of multidrug‐resistance (MDR) by interacting with membrane phospholipids. The permeation properties of MDR‐modulators and non‐modulators were studied by quantifying their ability to induce the leakage of Sulphan blue through the membrane of negatively charged unilamellar liposomes.
European Journal of Medicinal Chemistry | 1998
Marie-Gratia Kayirere; Abdallah Mahamoud; Jacqueline Chevalier; Jean-Claude Soyfer; Andrée Crémieux; Jacques Barbe
Abstract 4-Alkoxy-8-methyl-7-nitroquinolines, 4-alkylamino-8-methyl-7-nitroquinolines, 4-alkoxy-2,8-dimethylquinolines, 4-alkylthioquinolines were prepared from 8-methyl-7-nitro-4-quinolone, 8-methyl-7-nitro-4-chloro-quinoline, 2,8-dimethyl-4-quinolone and 4-hydroxyquinoline used as starting material. Compounds were characterized from 1H and 13C NMR spectra. These drugs were tested against selected gram−, gram+ and mycobacteria strains. A promising activity was observed against Mycobacterium smegmatis.
International Journal of Antimicrobial Agents | 2010
Jacqueline Chevalier; Abdallah Mahamoud; Milad Baitiche; Elissavet Adam; Miguel Viveiros; Adriana Smarandache; Andra Militaru; Mihail Lucian Pascu; Leonard Amaral; Jean-Marie Pagès
Amongst the three series of quinazoline derivatives synthesised and studied in this work, some molecules increase the antibiotic susceptibility of Gram-negative bacteria presenting multidrug-resistant phenotypes. N-alkyl compounds induced an increase in the activity of chloramphenicol, nalidixic acid and sparfloxacin, which are substrates of the AcrAB-TolC and MexAB-OprM efflux pumps in clinical isolates. These molecules are able to increase the intracellular concentration of chloramphenicol in efflux pump-overproducing strains. Their activity depends on the antibiotic structure, suggesting that different sites may be involved for the recognition of substrates by a given efflux pump. Quinazoline molecules exhibiting a nitro functional group are more active, and structure-activity relationship studies may be undertaken to identify the pharmacophoric group involved in the AcrB and MexB affinity sites.
Current Topics in Medicinal Chemistry | 2010
Jean-Marie Pagès; Sandrine Alibert-Franco; Abdallah Mahamoud; Jean-Michel Bolla; Anne Davin-Regli; Jacqueline Chevalier; Eric Garnotel
Antibiotic resistance mechanisms reported in Gram-negative bacteria are a worldwide health problem. The continuous dissemination of multi-drug resistant (MDR) bacteria drastically reduces the efficacy of our antibiotic “arsenal” and consequently increases the frequency of therapeutic failure. In MDR bacteria the over-expression of efflux pumps expel structurally-unrelated antibiotics decreasing their intracellular concentration. It is necessary to clearly define the molecular and genetic bases of the efflux pump in order to combat this mechanism. The characterization of efflux pumps, from genetic to structural studies, allows the definition of a new, original antiresistance bullet, the efflux pump inhibitor (EPI). This new class of antibacterial molecules may act conjointly to the usual antibiotic in order to restore its activity. Several families of EPIs have been now reported and described. The use of these EPIs promotes a significant increase of susceptibility to one or more antibiotics in strains or clinical isolates which were initially resistant. These EPIs may target different efflux targets, (i) the expression of genes that induces MDR, the transporters that pump the antibiotic out of bacterium, (ii) the assembly of membrane transporter complex involved in drug efflux, (iii) the energy involved in this active transport, (iv) the inhibition of the flux of molecules inside the efflux channel by competition or blocking (via steric hindrances). With the recent thorough characterization of the efflux pump AcrB at its structural and physiological level including the identification of drug affinity sites and kinetic parameters for some antibiotics, it is now possible to rationally develop an improved new generation of EPIs.
European Journal of Medicinal Chemistry | 2003
Sandrine Gallo; Siham Atifi; Abdallah Mahamoud; Christiane Santelli-Rouvier; Krisztina Wolfart; József Molnár; Jacques Barbe
Anti MDR activity of a series of acridine, pyridoquinoline, quinoline and pyridine analogous amines was evaluated. Interesting activity is displayed by tricyclic compounds. Besides ring size, influence of the side chain was studied.
Current Medicinal Chemistry | 2009
Sandrine Alibert-Franco; Bruno Pradines; Abdallah Mahamoud; Anne Davin-Regli; Jean-Marie Pagès
Chemoresistance is a general health problem concerning infectious diseases and cancer treatments. In this context, the worldwide dissemination of << pandrug >> and << multidrug>> resistant pathogens has severely compromised the efficacy of our antimicrobial weapons and dramatically increased the occurence of therapeutic failure. To efficiently combat multi-resistant pathogens, it is necessary to clearly define the molecular basis of the general resistance mechanism associated with the expression of active efflux pumps, which strongly restrict the intracellular concentration of antimicrobial drugs. Several families of efflux systems capable of multiple drug extrusion have been described. The activity of some efflux systems requires ATP hydrolysis for drug transport while others require a sodium or proton antiport. In this review we focus on two important human pathogens, Plasmodium falciparum and Pseudomonas aeruginosa, which exhibit a high level of antimicrobial resistance associated with the expression of efflux mechanisms. The efflux mechanisms and the development of efflux pump inhibitors (EPIs) are discussed regarding these two pathogens.
International Journal of Antimicrobial Agents | 2003
Sandrine Gallo; Jacqueline Chevalier; Abdallah Mahamoud; Annie Eyraud; Jean-Marie Pagès; Jacques Barbe
Enterobacter aerogenes is a Gram-negative bacteria frequently responsible for nosocomial respiratory tract infections. Strains resistant to chloramphenicol are frequently isolated. Alkoxy and thio-alkoxyquinolines have a potential to act as chemosensitizers that would render multi-drug-resistant (MDR) bacterial infections susceptible to antibiotics to which they were originally resistant. Several new quinoline derivatives have been prepared, characterized and studied for their ability to increase chloramphenicol sensitivity of E. aerogenes 27, a clinical strain that exhibits the MDR phenotype. Drugs investigated were either quinoline ethers or quinoline thio-ethers. Thio-ethers are much more efficient in increasing chloramphenicol sensitivity than other corresponding ethers. In particular, 4-piperidinoethylthio-quinoline increases the strain sensitivity to chloramphenicol by about 20 times at 2 mM concentration. Similarly, sensitivity to quinolone antibiotics dramatically increases. Because these quinoline derivatives act as inhibitors of the drug efflux pump responsible for bacterial resistance to chloramphenicol, they may serve as adjunct to conventional therapy of E. aerogenes infections.